Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31259418 | 0.79 | ALDH1A1 (0.46) | ALDH1A1PKMSLC1A2KMT2AATM | |
| SCHEMBL432176 | 0.77 | ALDH1A1 (0.44) | ALDH1A1PKMSLC1A2KMT2AATM | |
| SCHEMBL31723977 | 0.77 | LMNA (0.37) | ALDH1A1PKMSLC1A2KMT2AATM | |
| SCHEMBL202493 | 0.75 | ALDH1A1 (0.43) | ALDH1A1PKMSLC1A2KMT2AATM | |
| SCHEMBL1442379 | 0.75 | ALDH1A1 (0.43) | ALDH1A1PKMSLC1A2KMT2AATM | |
| SCHEMBL526394 | 0.75 | ALDH1A1 (0.43) | ALDH1A1PKMSLC1A2KMT2AATM | |
| SCHEMBL9901995 | 0.75 | ALDH1A1 (0.43) | ALDH1A1PKMSLC1A2KMT2AATM | |
| SCHEMBL57078 | 0.75 | KMT2A (0.53) | ALDH1A1PKMSLC1A2KMT2AATM | |
| SCHEMBL1564214 | 0.75 | KMT2A (0.53) | ALDH1A1PKMSLC1A2KMT2AATM | |
| SCHEMBL871730 | 0.73 | ALDH1A1 (0.35) | ALDH1A1PKMSLC1A2KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4344745-A2 | SUSTAINED RELEASE BIODEGRADABLE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND CYCLOSPORINE | Ocular Therapeutix, Inc. (US) | 2024-04-03 | — | — | EP | claimed |
| EP-3973952-B1 | SUSTAINED RELEASE BIODEGRADABLE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND CYCLOSPORINE | OCULAR THERAPEUTIX INC (US) | 2024-02-14 | — | — | EP | claimed |
| EP-4216929-A1 | SUSTAINED RELEASE BIODEGRADABLE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND AN ACTIVE AGENT | Ocular Therapeutix, Inc. (US) | 2023-08-02 | — | — | EP | claimed |
| WO-2022066891-A1 | SUSTAINED RELEASE BIODEGRADABLE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND AN ACTIVE AGENT | OCULAR THERAPEUTIX, INC. (US) | 2022-03-31 | — | — | WO | claimed |
| WO-2022066884-A1 | SUSTAINED RELEASE BIODEGRADALBE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND CYCLOSPORINE | OCULAR THERAPEUTIX, INC. (US) | 2022-03-31 | — | — | WO | claimed |
| EP-3973952-A1 | SUSTAINED RELEASE BIODEGRADABLE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND CYCLOSPORINE | Ocular Therapeutix, Inc. (US) | 2022-03-30 | — | — | EP | claimed |
| EP-4665307-A1 | BIODEGRADABLE MICROPARTICLES FOR SUSTAINED DRUG DELIVERY, METHODS OF PREPARATION AND USE THEREOF | Ocular Therapeutix, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250268818-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | OCULAR THERAPEUTIX INC (US) | 2025-08-28 | — | — | US | disclosed |
| US-12329853-B2 | Compositions and methods for treating ocular diseases | OCULAR THERAPEUTIX, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20250120906-A1 | SUSTAINED RELEASE BIODEGRADABLE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND AN ACTIVE AGENT | OCULAR THERAPEUTIX INC (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250114373-A1 | INTRACANALICULAR INSERT COMPRISING AN ANTIMICROBIAL AGENT | OCULAR THERAPEUTIX, INC. | 2025-04-10 | — | — | US | disclosed |
| US-20250108003-A1 | METHODS OF TREATING ALLERGIC CONJUNCTIVITIS | OCULAR THERAPEUTIX INC (US) | 2025-04-03 | — | — | US | disclosed |
| US-20250064760-A1 | INTRACANALICULAR INSERT COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY AGENT | OCULAR THERAPEUTIX, INC. | 2025-02-27 | — | — | US | disclosed |
| EP-3973952-A1 | SUSTAINED RELEASE BIODEGRADABLE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND CYCLOSPORINE | Ocular Therapeutix, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20220087931-A1 | SUSTAINED RELEASE BIODEGRADABLE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND CYCLOSPORINE | BARINGS FINANCE LLC, AS AGENT | 2022-03-24 | — | — | US | disclosed |
| US-20220087932-A1 | SUSTAINED RELEASE BIODEGRADABLE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND CYCLOSPORINE | BARINGS FINANCE LLC, AS AGENT | 2022-03-24 | — | — | US | disclosed |
| WO-2022015940-A1 | OCULAR INSERT CONTAINING A GLUCOCORTICOID | OCULAR THERAPEUTIX, INC. (US) | 2022-01-20 | — | — | WO | disclosed |
| WO-2021222117-A1 | METHODS OF TREATING ALLERGIC CONJUNCTIVITIS | OCULAR THERAPEUTIX, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-20210251893-A1 | Compositions and Methods for Treating Ocular Diseases | OCULAR THERAPEUTIX, INC. | 2021-08-19 | — | — | US | disclosed |
| EP-3861985-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | Ocular Therapeutix, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12329853-B2 | Compositions and methods for treating ocular diseases | PDE6C, PDE6H, PDE6A | ALDH1A1 2175/4885PKM 3497/4885SLC1A2 2119/4885 |
| US-20250108003-A1 | METHODS OF TREATING ALLERGIC CONJUNCTIVITIS | NR3C1, SERPINA6, TSLP | ALDH1A1 1676/4885PKM 4135/4885SLC1A2 2153/4885 |
| US-20250120906-A1 | SUSTAINED RELEASE BIODEGRADABLE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND AN ACTIVE AGENT | IDUA, ABCB11, SLC47A2 | ALDH1A1 372/4885PKM 3852/4885SLC1A2 1089/4885 |
| US-20250268818-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | PDE6C, PDE6H, PDE6A | ALDH1A1 2175/4885PKM 3497/4885SLC1A2 2119/4885 |
| US-20220087931-A1 | SUSTAINED RELEASE BIODEGRADABLE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND CYCLOSPORINE | SUCLG1, FKBP8, FKBP1A | ALDH1A1 1026/4885PKM 4395/4885SLC1A2 1276/4885 |
| US-20210251893-A1 | Compositions and Methods for Treating Ocular Diseases | PDE6C, PDE6H, PDE6A | ALDH1A1 2175/4885PKM 3497/4885SLC1A2 2119/4885 |
| US-20250064760-A1 | INTRACANALICULAR INSERT COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY AGENT | TNF, OPRL1, PTGES | ALDH1A1 231/4885PKM 4070/4885SLC1A2 1670/4885 |
| US-20220087932-A1 | SUSTAINED RELEASE BIODEGRADABLE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND CYCLOSPORINE | SUCLG1, FKBP8, FKBP1A | ALDH1A1 1026/4885PKM 4395/4885SLC1A2 1276/4885 |
| US-20250114373-A1 | INTRACANALICULAR INSERT COMPRISING AN ANTIMICROBIAL AGENT | ABCB11, IDE, YIF1A | ALDH1A1 271/4885PKM 4015/4885SLC1A2 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.